70 results
6-K
EX-99.2
IMCR
Immunocore Holdings plc
12 May 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:00am
reflects both a decrease in headcount and a slowdown of some internal research and development activities as a result of the COVID-19 pandemic as noted … with any of the above, including any delays or other impacts as a result of the COVID-19 pandemic.
We held cash and cash equivalents of £313.1 million
6-K
EX-99.1
IMCR
Immunocore Holdings plc
9 Sep 22
Cautionary Note Regarding Forward Looking Statements
4:29pm
, but are not limited to, the impact of the ongoing and evolving COVID-19 pandemic on the Company’s business, strategy, clinical trials and financial … as a result of the COVID-19 pandemic, war in Ukraine or global geopolitical tension; Immunocore’s ability to obtain and maintain regulatory approvals for its
6-K
EX-99.1
IMCR
Immunocore Holdings plc
14 Nov 22
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting
7:59am
and the ongoing and evolving COVID-19 pandemic on the Company’s business, strategy, clinical trials and financial position, strategy and anticipated … or future product candidates or commercial supply of KIMMTRAK or any future approved products, including as a result of the COVID-19 pandemic, war
6-K
IMCR
Immunocore Holdings plc
8 Dec 22
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
4:59pm
to, the impact of worsening macroeconomic conditions and the ongoing and evolving COVID-19 pandemic on the Company’s business, strategy, clinical trials … as a result of supply chain disruptions, the COVID-19 pandemic, the war in Ukraine or global geopolitical tension; the Company’s ability to obtain and maintain
6-K
EX-99.2
IMCR
Immunocore Holdings plc
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
trials, including public health emergencies such as the ongoing and evolving COVID-19 pandemic;
after reviewing trial results, our collaboration … candidates in a sufficient quantity, including as a result of supply chain disruptions caused by the COVID-19 pandemic and war in Ukraine and global
6-K
EX-99.2
uosqx6c12x5j ux
10 Nov 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:01am
6-K
EX-99.1
rjf7s
8 Dec 22
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
4:59pm
6-K
EX-99.1
pzcjac nm3ta2yi78hw
9 Sep 22
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress
12:33pm
6-K
EX-99.2
3v4p dogivz4higpla
11 Aug 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:00am
6-K
tzl6zeyed6spxhoivqt
18 Apr 23
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival
4:15pm
6-K
EX-99.1
1unj7x0sih47zh54zp0l
18 Apr 23
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival
4:15pm
6-K
EX-99.4
enmp3j1vmryv ru
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
6-K
EX-99.1
enefbye cf
5 Jun 23
Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
9:20am
6-K
3b38h5sham82jei1vcz8
5 Jun 23
Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
9:20am
6-K
EX-99.2
pcx00pofx0w
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.2
aill5
11 May 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:08am
6-K
qmz2j cdfqvk7sk0
14 Nov 22
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting
7:59am
6-K
EX-99.3
tvuhi005pekic02dwis
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.1
ect8zbq 3k7vggi2tfw
2 Dec 22
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors
5:08pm
6-K
EX-99.2
q290u7lkrjwc2wffs
9 Sep 22
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress
12:33pm